Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220983 | 1.00 | TSHR (0.46) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL6221209 | 0.83 | TSHR (0.47) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL6218130 | 0.83 | TSHR (0.47) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL6218131 | 0.83 | TSHR (0.47) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL6221214 | 0.83 | TSHR (0.47) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL16264932 | 0.81 | MAPT (0.54) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL5125736 | 0.80 | CASP1 (0.42) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL5125735 | 0.80 | CASP1 (0.42) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL5318594 | 0.79 | CES2 (0.59) | TSHRCASP1LMNAKMT2AMEN1 | |
| SCHEMBL18591425 | 0.78 | TSHR (0.49) | TSHRCASP1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165236-A1 | Process for the preparation of Imiquimod and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-07-28 | — | — | US | disclosed |
| EP-1529781-A1 | A process for the preparation of Imiquimod and intermediates thereof | Dipharma S.p.A. (IT) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165236-A1 | Process for the preparation of Imiquimod and intermediates thereof | MYD88, TLR7, MAVS | TSHR 4585/4885CASP1 456/4885LMNA 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.